Preclinical and clinical data have suggested that blocking the MAP kinase signaling cascade by BRAF inhibitors such as encorafenib, and MEK inhibitors such as binimetinib, can block not only growth suppression of tumor cells, but can also lead to a disturbance in the retinal pigment epithelium [10]. The gene discussed is BRAF; the disease is neoplasm.